(Boursier.com) — inventive a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of non-alcoholic steatohepatitis and other diseases with an unmet medical need, and Echosens, a technology company offering a wide range of diagnostic solutions for liver health, announce today that they are jointly launching an initiative to raise awareness of NASH and facilitate access to screening for patients who are at risk of developing this disease.
NASH is a chronic and progressive metabolic disease of the liver which, if not diagnosed or treated, can progress to cirrhosis or liver cancer and make liver transplantation necessary. Although NASH is often referred to as a “silent” disease, patients who suffer from it see their quality of life really affected and present an above-average risk of cardiovascular and hepatic complications.
NASH is a disease whose prevalence is both high and growing: it affects between 1.5% and 6.45% of the world’s population, a proportion that is expected to increase to 63% by 2030. There are therefore an urgent need to diagnose patients in whom the disease is at high risk of progression. It is with the aim of facilitating access to screening by FibroScan in local communities that Inventiva and Echosens have decided to join forces.
This awareness and screening program will take place in ten at-risk communities in the United States and Europe and will be supported by experts in hepatology as well as patient associations and local organizations.
©2023 Boursier.com